ALXO · Alx Oncology Holdings Inc

Track ALXO — free

$1.94 +0.04 (+2.11%) At close · Sep 11

Russell 2000 member Rebalance outlook locked

Market Cap

$268.26M

138.28M

Up next

Latest filing: 10-Q

filed Aug 6, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

—

Trailing 12 months

Net income (TTM)

−$80.89M

Trailing 12 months

Revenue growth YoY

-59.3%

Year over year

Operating margin

—

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

-26.4%

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

$128.52M

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+153.8%

Year over year · more shares

Price change (1Y)

+64.4%

Trailing year

Short interest

5.1%

Latest settlement · 12.3 days to cover

View all 115 metrics

Equibles Rating

blended score · not investment advice

Overall

Sell

SellHoldBuy

Technical Neutral Momentum Weak Sentiment Neutral Fundamentals Strong Quant / Vol Very High

Market backdrop VIX 15.8 · calm Equity put/call 0.58

Technical

price trend

Neutral

50 / 200-day cross No cross

Price vs 200-day avg +6%

above

Price vs 50-day avg −4%

below

RSI (14) 47

neutral

MACD trend Negative

52-week position 57%

mid-range

Momentum

relative strength

Weak

1-month return 0%

trailing

6-month return −11%

trailing

YTD return +72%

this year

Relative strength −29%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $2 › 200d $2 — 50d above 200d

Institutional flow Accumulating

+34% holders QoQ · +36 funds added

Insider flow Distributing

Net -$8.3K over 90 days · 100% sells

Short interest Falling

5.11% of float · ▼ -7.2% MoM · 12.3 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

94 holders — mid 3-yr range

Squeeze score 70

high risk · 0–100

Fundamentals

Strong

EPS growth +26%

Y/Y

Free cash flow $-84.4M

Balance sheet $6.6M

net cash

Quant / Vol

risk profile

Very High

Volatility 96%

annualized · 1-yr

Max drawdown −50%

past year

ATR 5.9%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral

1 · 4 · 1

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+6% Bullish

Price vs 50-day avg

−4% Neutral

RSI (14)

47 Neutral

MACD trend

Negative Bearish

52-week position

57% Neutral

Market signals — smart money & positioning

Bullish · 2 of 6

Trend (MA cross) No cross

50d $2 › 200d $2 — 50d above 200d

Institutional flow Accumulating

+34% holders QoQ · +36 funds added

Insider flow Distributing

Net -$8.3K over 90 days · 100% sells

Short interest Falling

5.11% of float · ▼ -7.2% MoM · 12.3 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

94 holders — mid 3-yr range

Price context

position in its 52-week range

Range low $1 Now $2 · 57% Range high $3

vs 200-day avg +6% vs 50-day avg -4%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
ALXO Alx Oncology Holdings Inc this stock	$268.26M	+71.7%	—	—	5.1%
VRTX Vertex Pharmaceuticals Inc / Ma	$130.64B	+13.7%	+46.2%	30.0	1.8%
REGN Regeneron Pharmaceuticals, Inc.	$80.46B	+1.2%	+20.8%	19.4	2.5%
ARGX Argenx SE	$61.22B	+17.1%	—	—	2.0%
MRNA Moderna, Inc.	$57.48B	+388.2%	+4.3%	—	9.8%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

% held: 76.1%
Net QoQ: +10.9M sh
Top holder: RA CAPITAL MANAGEMENT, L.…

Held Float

View

Held by Funds

Fund positions

View

Short & Settlement

Short Interest Falling

Shares short

7.1M

Days to cover: 12.3d
Change: -547.4K sh

View

Short Volume

Short vol %

53%

As of: Sep 11, 2026

Short Total

View

Fails to Deliver

FTD shares

8.5K

Value: $16.6K
As of: Aug 14, 2026

View

Off-Exchange

Off-exchange %

65.7%

Week of: Aug 3, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$8.3K

Buyers / Sellers: 0 / 2

Buyers Sellers

View

Financials

Revenue (FY)

Net income (FY): $-101.7M
EPS diluted: $-1.90

View

Filings

SEC Filings

Latest

8-K

Filed: Aug 6, 2026
This year: 17

View

Proposed Sales

Value

$135.2K

Shares: 20.0K
Filed: Jul 11, 2024

View

Earnings & Events

Earnings Calls

Last call

Jun 3, 2026

View

Performance

	5D	20D	120D	MTD	YTD
ALXO	-4.4%	+0.0%	-11.0%	+0.5%	+71.7%
SPY	-1.2%	-1.8%	+17.8%	-0.4%	+12.1%
vs SPY	-3.3%	+1.8%	-28.9%	+0.9%	+59.6%

Key facts CIK 1810182 CUSIP 00166B105 13F (30d) 42 filings 42 filers Visit website Investor relations

ALXO · Alx Oncology Holdings Inc

Price & Indicators

Up next

Metrics snapshot

Equibles Rating

Technicals

Key metrics

Versus peers

At a glance

Performance